Exploring MMP14 as a Prognostic and Immune Biomarker in Lung Cancer

1

Lung cancer deaths are projected to increase by 67% by 2040, with non-small cell lung cancer (NSCLC) being the most prevalent subtype.
2

MMP14 is a key factor in tumor invasion and metastasis, with its expression linked to poor prognosis in lung cancer and other malignancies.
3

The study identifies MMP14 as a potential prognostic biomarker in lung adenocarcinoma (LUAD), correlating its expression with tumor progression.
4

MMP14's expression is regulated by NSUN2-mediated RNA methylation, highlighting the role of epigenetic modifications in lung cancer.
5

This research underscores MMP14's potential as a therapeutic target, offering insights for precision oncology in LUAD treatment.

1